Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers

Download All
Get an expert’s take on the evolving role of immune checkpoint inhibitors in managing advanced gastric and esophageal cancers with this program, which features a series of ClinicalThought™ commentaries on emerging clinical data, managing immune-related adverse events, and key biomarkers of response.
Tanios Bekaii-Saab
Tanios Bekaii-Saab, MD, FACP
Axel Grothey Headshot
Axel Grothey, MD
Steven Maron, MD

ClinicalThought

Gain expert insight on the use of ICIs either as monotherapy or in combination with targeted agents when managing patients with gastric or GEJ cancer, as informed by recent data from the 2019 Gastrointestinal Cancers Symposium.

Steven Maron, MD Released: February 26, 2019

With widening use of immune checkpoint inhibitors in patients with gastroesophageal cancer, it is critical for clinicians to stay abreast of the unique adverse events associated with these agents

Axel Grothey Headshot Axel Grothey, MD Released: March 22, 2019

Which of our patients with advanced gastric/GEJ cancers are most likely to benefit from later-line treatment with PD-1 inhibitors? Here’s my take on applying the latest evidence to the clinic.

Tanios Bekaii-Saab Tanios Bekaii-Saab, MD, FACP Released: July 18, 2019

Module

Gain expert perspectives on leveraging immune checkpoint inhibitors to optimally manage advanced gastric/GEJ cancers including identifying patients most likely to benefit, managing immune-related adverse events, and insights on emerging data with combination regimens.

Tanios Bekaii-Saab Tanios Bekaii-Saab, MD, FACP Axel Grothey Headshot Axel Grothey, MD Steven Maron, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: August 9, 2019 Expired: No longer available for credit
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings